FGFs and FGFRs as Targets for Anticancer Therapy in Lung Cancer and Glioblastoma

Aim of this research project is to clarify the role of fibroblast growth factor (FGF) receptor-dependent signals in development and malignant progression of major solid tumor types with a focus lung cancer and glioblastomas and their potential as targets for anticancer strategies. In lung cancer, resistance development against FGFR inhibitors in squamous cell carcinoma with FGFR1 amplification is followed. Moreover, a major focus is laid on the impact of FGFR4 on the aggressiveness of solid tumors with a focus on lung cancer.

Inhibition of specific FGFRs by dominant negative (dn) or kinase dead (kd) adenoviral constructs prolongs survival of SCID mice bearing a human glioblastoma xenograft.

Claudia Engelmaier, PhD
N.N., Master Student

Cooperations:
B. Grasl-Kraupp, M. Grusch, K. Holzmann, B. Marian (Institute of Cancer Research)
G. Widhalm, S. Wolfsberger, E. Knosp (AKH, Department for Neurosurgery)
J. Hainfellner (AKH, Department for Neuropathology)
S. Spiegl-Kreinecker, G.Wurm (Landesnervenklinik Wagner-Jauregg, Linz)
AKH Vienna